newsfilter
← Latest News
Business Wire·

NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses

Growth driven by efficient Avenova® direct-to-consumer e-marketing programs NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports preliminary net revenue for its eyecare and wound care business for the first